Acumen Pharmaceuticals
ABOS
66 hedge funds and large institutions have $179M invested in Acumen Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 12 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
42% more capital invested
Capital invested by funds: $127M → $179M (+$52.6M)
25% more funds holding
Funds holding: 53 → 66 (+13)
10.46% more ownership
Funds ownership: 64.17% → 74.63% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $1.21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$31.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$17.5M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$17.4M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$13.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.67M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.1M |
| 3 |
WP
WMS Partners
Towson,
Maryland
|
-$473K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$407K |
| 5 |
KIA
Knollwood Investment Advisory
Hunt Valley,
Maryland
|
-$309K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Squarepoint
New York
| – | -$50.2K | -10,445 | Closed |
|
|
FDCDDQ
77
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$4.29K | -892 | Closed |
|
78
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.2K | -194 | -66% |
|
ABOS Hedge Fund Activity: Q3 2023 in Review
66 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q3 2023, worth a combined $179M — up 42% from $127M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ABOS positions and 12 closed out — a net gain of 13 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was RA Capital Management, adding an estimated $31.9M. The largest seller was Deep Track Capital, cutting an estimated $8.67M.
- 66 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q3 2023, up from 53 in Q2 2023.
- Funds reported $179M of Acumen Pharmaceuticals stock for Q3 2023, up 42% quarter-over-quarter.
- 25 funds opened new Acumen Pharmaceuticals positions in Q3 2023 and 12 closed out, a net change of +13 holders.
- The largest Acumen Pharmaceuticals buyer in Q3 2023 was RA Capital Management, an estimated $31.9M added.
- The largest Acumen Pharmaceuticals seller in Q3 2023 was Deep Track Capital, an estimated $8.67M sold.
Based on aggregated 13F filings for Q3 2023.